Fitusiran

Generic Name: Fitusiran

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1499251-18-1

Unique Ingredient Identifier: SV9W47ZLE1

Background: Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.

Related Clinical Trials:

The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy